ArticleBMJ paediatrics open2026
Polypharmacy and adverse drug reactions among hospitalised children: determinants and clinical and economic impact in a multicentre prospective cohort and nested matched case-control study in Northwest Ethiopia.
Article in BMJ paediatrics open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedication-related harm in children is a major global public health concern, with adverse drug reactions (ADRs) contributing substantially to morbidity and healthcare costs. This study aimed to estimate ADR incidence, identify determinants of polypharmacy, examine its association with ADR risk and assess the clinical and economic impact of ADRs.
methodsA multicentre prospective cohort study with a nested case-control component was conducted among paediatric inpatients in four comprehensive specialised hospitals in Northwest Ethiopia. Cox proportional hazards regression identified predictors of ADR occurrence, and logistic regression assessed determinants of polypharmacy. For the nested case-control analysis, categorical outcomes were compared using the McNemar test, while continuous outcomes were compared using a generalised linear model. Statistical significance was set at p<0.05 with 95% CIs.
resultsAmong 1247 paediatric inpatients, 320 (25.7%) experienced at least one ADR, totalling 347 events (22.5 per 1000 patient-days). Independent predictors of ADRs included off-label drug use (adjusted HR (AHR) 1.3, 95% CI 1.0 to 1.6), immunocompromised status (AHR 1.6, 95% CI 1.2 to 1.9), three disease conditions (AHR 1.4, 95% CI 1.0 to 1.9), four or more disease conditions (AHR 1.9, 95% CI 1.2 to 2.4), systemic anti-infective use (AHR 1.4, 95% CI 1.1 to 1.8) and excessive polypharmacy (AHR 1.4, 95% CI 1.0 to 1.9). Polypharmacy (≥5 medications) was observed in 56.7% of patients and was associated with multiple prescribers (AOR 1.48, 95% CI 1.1 to 2.0), hospital stay ≥14 days (AOR 1.60, 95% CI 1.1 to 2.6), each additional antibiotic (AOR 2.5, 95% CI 2.2 to 2.9) and each additional intravenous medication (AOR 2.6, 95% CI 2.1 to 3.0). ADR cases had longer hospital stays (15.7±5.6 vs 12.2±3.0 days; β=0.213, 95% CI 0.171 to 0.256) and higher medical costs (6027±1037.6 vs 4483.8±703.9 Ethiopian birr; β=0.296, 95% CI 0.270 to 0.322) than controls.
conclusionsADRs are common among hospitalised children in Northwest Ethiopia and are associated with prolonged hospital stay and increased healthcare costs. Polypharmacy is also highly prevalent, driven by the complexity of care, and independently increases the risk of ADRs. Strengthening pharmacovigilance and promoting rational prescribing with targeted monitoring of high-risk children may help to reduce medication-related harm and economic burden in paediatric patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.